Search stocks

Find any stock by ticker or company name

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Избранное
Рынки
Календарь
Скринер
Новости
О нас

BLLN - BillionToOne, Inc. Последние новости | Finranks

Home

/

BLLN

B

BillionToOne, Inc. (BLLN)

NMS – Цена в реальном времени. Валюта: USD

97.26

-0.68 (-0.69%)

Рынок открыт: Aug 12, 2026, 12:51 PM EDT

98.54

+0.59 (0.61%)

Предыдущая сессия: Aug 11, 2026, 7:34 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

BillionToOne: A Softer Quarter After Heightened Expectations

BillionToOne: A Softer Quarter After Heightened Expectations

BillionToOne experienced a sharp post-earnings sell-off despite maintaining full-year guidance and strong year-over-year revenue growth. Second quarter results showed slowing sequential growth, softer average selling prices, and significant margin compression versus Q1. The company trades at ~10x sales, a premium to May levels, with the growth story intact but near-term valuation less attractive.

BillionToOne (BLLN) Reports Q2 Earnings: What Key Metrics Have to Say

BillionToOne (BLLN) Reports Q2 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for BillionToOne (BLLN) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Billiontoone Q2 Earnings Call Highlights

Billiontoone Q2 Earnings Call Highlights

Billiontoone NASDAQ: BLLN reported second-quarter 2026 revenue growth of 64% year over year, driven by higher testing volumes and average selling prices across its prenatal and oncology businesses. The molecular diagnostics company also posted positive operating income and free cash flow while reiterating its full-year revenue outlook.

BillionToOne Reports Second Quarter 2026 Results and Reiterates 2026 Revenue Guidance

BillionToOne Reports Second Quarter 2026 Results and Reiterates 2026 Revenue Guidance

MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today reported its financial results for the second quarter ended June 30, 2026 and reiterated guidance for full year 2026.

Read Between These Lines As Eli Lilly, Hot IPO And More Face Key Test

Read Between These Lines As Eli Lilly, Hot IPO And More Face Key Test

As stocks like Eli Lilly, Twilio, Hinge Health and more move ahead of earnings report, pay attention to these chart lines.

Видео

No Data

There is no data to display

Пресс-релизы

BillionToOne Reports Second Quarter 2026 Results and Reiterates 2026 Revenue Guidance

BillionToOne Reports Second Quarter 2026 Results and Reiterates 2026 Revenue Guidance

MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today reported its financial results for the second quarter ended June 30, 2026 and reiterated guidance for full year 2026.